Dextroamphetamine, immediate release amphetamine sulfate and. Lisdexamfetamine is also used to treat moderate to severe binge eating disorder. In addition, results were imprecise for many outcomes because the number of studies and included participants was low. Amphetamine sulfate, mixed amphetamine salts, dextroamphetamine and lisdexamfetamine are prescription medications that are used to treat individuals with attention-deficit hyperactivity disorder (ADHD). N o study was at low risk of bias overall, namely because it was possible for participants to know which treatments they were taking. The three amphetamine based medicines they considered (dextroamphetamine, lisdexamphetamine and mixed amphetamine salts (MAS)) all reduced ADHD symptoms. There were no differences in effectiveness between amphetamines and guafacine, modafinil, or paroxetine. The review authors found low- to very low-quality evidence that amphetamines reduce the severity of ADHD symptoms in the short term, but do not improve retention to treatment and are associated with higher attrition due to adverse events.

All studies were placebo controlled and three also included an active comparator: guanfacine, modafinil or paroxetine. In a two-part study, children with attention deficit-hyperactivity disorder (ADHD) using the dextroamphetamine transdermal system (d-ATS) saw a significant improvement in symptoms in a laboratory classroom. The studies examined three types of amphetamines: dexamphetamine (10.2 mg/d to 21.8 mg/d), lisdexamfetamine (30 mg/d to 70 mg/d), and mixed amphetamine salts (12.5 mg/d to 80 mg/d). A transdermal amphetamine therapy was effective at treating pediatric ADHD, according to a phase II trial. Sixteen studies were funded by pharmaceutical companies, one study was publicly funded, and two studies did not report their funding sources. Eighteen studies were conducted in the USA and one study was conducted in both Canada and the USA. The review included 19 studies with 2521 participants, most of whom were middle-aged (35.3 years), Caucasian males (57.2%) with a combined type of ADHD (78.8%).

This recently updated Cochrane Intervention Review examined the efficacy and safety of amphetamines for adults with ADHD.

Amphetamine adhd